Monte Rosa Therapeutics (GLUE) Competitors $4.79 -0.16 (-3.23%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.79 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. CVAC, NTLA, CALT, HROW, PRAX, PAHC, PHVS, SYRE, GPCR, and AVDLShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include CureVac (CVAC), Intellia Therapeutics (NTLA), Calliditas Therapeutics AB (publ) (CALT), Harrow (HROW), Praxis Precision Medicines (PRAX), Phibro Animal Health (PAHC), Pharvaris (PHVS), Spyre Therapeutics (SYRE), Structure Therapeutics (GPCR), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Its Competitors CureVac Intellia Therapeutics Calliditas Therapeutics AB (publ) Harrow Praxis Precision Medicines Phibro Animal Health Pharvaris Spyre Therapeutics Structure Therapeutics Avadel Pharmaceuticals CureVac (NASDAQ:CVAC) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Is CVAC or GLUE more profitable? CureVac has a net margin of 35.44% compared to Monte Rosa Therapeutics' net margin of 3.86%. CureVac's return on equity of 30.89% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CureVac35.44% 30.89% 25.54% Monte Rosa Therapeutics 3.86%2.65%1.65% Which has preferable valuation and earnings, CVAC or GLUE? CureVac has higher revenue and earnings than Monte Rosa Therapeutics. CureVac is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$579.18M2.10$175.50M$0.925.88Monte Rosa Therapeutics$75.62M3.90-$72.70M$0.0859.88 Which has more volatility and risk, CVAC or GLUE? CureVac has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Does the media favor CVAC or GLUE? In the previous week, CureVac's average media sentiment score of 1.79 beat Monte Rosa Therapeutics' score of 0.00 indicating that CureVac is being referred to more favorably in the media. Company Overall Sentiment CureVac Very Positive Monte Rosa Therapeutics Neutral Do insiders and institutionals believe in CVAC or GLUE? 17.3% of CureVac shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 6.9% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer CVAC or GLUE? CureVac currently has a consensus target price of $6.83, indicating a potential upside of 26.31%. Monte Rosa Therapeutics has a consensus target price of $15.33, indicating a potential upside of 220.11%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryCureVac beats Monte Rosa Therapeutics on 8 of the 15 factors compared between the two stocks. Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$294.63M$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio59.8817.6228.8823.80Price / Sales3.90309.96440.8796.33Price / CashN/A41.6335.0756.59Price / Book1.328.488.255.54Net Income-$72.70M-$55.06M$3.25B$259.97M7 Day Performance-15.52%-3.99%-3.75%-4.67%1 Month Performance-5.05%8.53%2.99%3.28%1 Year Performance19.45%6.51%25.35%17.92% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics1.2715 of 5 stars$4.79-3.2%$15.33+220.1%+19.5%$294.63M$75.62M59.8890Gap DownCVACCureVac4.4448 of 5 stars$5.39-0.6%$6.83+26.8%+56.8%$1.21B$579.18M5.86880News CoveragePositive NewsNTLAIntellia Therapeutics4.5819 of 5 stars$11.64-5.6%$33.37+186.7%-51.8%$1.21B$45.57M-2.23600News CoverageUpcoming EarningsGap DownCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180HROWHarrow2.5022 of 5 stars$31.76-2.8%$63.83+101.0%+32.3%$1.17B$199.61M-56.71180Upcoming EarningsPRAXPraxis Precision Medicines2.7142 of 5 stars$54.22-4.2%$94.11+73.6%-4.7%$1.10B$8.55M-5.06110Analyst ForecastPAHCPhibro Animal Health4.1278 of 5 stars$26.50-5.1%$24.40-7.9%+47.2%$1.07B$1.19B33.971,940Positive NewsDividend AnnouncementPHVSPharvaris1.7397 of 5 stars$19.88+0.5%$36.20+82.1%+23.6%$1.04BN/A-6.6030Positive NewsSYRESpyre Therapeutics2.2536 of 5 stars$16.97-1.9%$53.40+214.7%-37.9%$1.02B$890K-4.5073News CoverageUpcoming EarningsGap DownGPCRStructure Therapeutics2.041 of 5 stars$17.80-0.2%$76.17+327.9%-51.0%$1.02BN/A-20.46136News CoverageUpcoming EarningsGap UpAVDLAvadel Pharmaceuticals2.6677 of 5 stars$10.51-1.8%$18.33+74.4%-32.1%$1.02B$169.12M-38.9370News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies CVAC Alternatives NTLA Alternatives CALT Alternatives HROW Alternatives PRAX Alternatives PAHC Alternatives PHVS Alternatives SYRE Alternatives GPCR Alternatives AVDL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
